This article first appeared on GuruFocus .
Release Date: May 26, 2026
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
Positive Points
-
Jubilant Ingrevia Ltd ( BOM:543271 ) reported the highest quarterly revenue and EBITDA in Q4 FY26 compared to the last 14 quarters, showcasing strong execution.
-
The company effectively managed the Middle East crisis with no force majeure and zero production loss.
-
Successful dispatch of the newly constructed AgroCDMO facility and acquisition of Remedex to boost the human nutrition business.
-
Strong growth in specialty chemicals, nutrition, and personal care markets, driven by robust demand and price increases.
-
The company has a robust opportunity pipeline with 100+ opportunities and a potential of Rs 3,500 crore, indicating future growth prospects.
Negative Points
-
Despite strong performance, the company faces challenges from volatile pricing in the chemical intermediates business.
-
The CDMO business, while growing, does not disclose exact revenue figures, which may limit transparency.
-
The company is naturally hedged against currency fluctuations, but benefits from rupee depreciation are not straightforward.
-
The semiconductor chemicals segment is experiencing slow ramp-up due to cautious customer adoption.
-
The agrochemical industry is moving slowly with massive cost pressures from China, affecting growth pace.
Q & A Highlights
-
Warning! GuruFocus has detected 2 Warning Sign with BOM:543271.
-
Is BOM:543271 fairly valued? Test your thesis with our free DCF calculator.
Q: How should we think about the spread in the chemical intermediates business in Q1, given the sharp improvement in acetic anhydride and acetic acid prices? Should we expect any inventory losses beyond Q1? A: (Unidentified_4) We have seen benefits from our approach of maintaining raw material inventory and locking in prices at the right time. These benefits are expected to continue into Q1. While acetic acid prices are coming down, we have been thoughtful in purchasing inventory, and any inventory impact should be minimized within this quarter or early next quarter.
Q: What was the revenue for the CDMO business in FY26, and is it classified under specialty chemicals or nutrition? A: (Unidentified_4) All CDMO revenues are recognized within the specialty business. While we don't disclose exact numbers, the CDMO business has been growing at a healthy rate of 30% to 40% annually. We expect further acceleration in growth in FY27 with new contracts.
Q: Can you offer any quantification regarding the expected sequential growth in EBITDA for the upcoming quarters and the full year? A: (Unidentified_4) We aim for at least 20% year-on-year growth in EBITDA on a full-year basis. While quarterly growth rates can be staggered due to contract timing, we maintain our overall guidance of achieving 20% growth in EBITDA through the year.
Q: What are the specific growth levers or strategic initiatives that give management confidence in achieving aggressive targets of three times revenue and four times EBITDA in the next four years? A: (Unidentified_4) Achieving 20% to 25% growth annually will keep us on track. We are confident in reaching our FY30 EBITDA targets organically, assuming stable pricing. Recent disruptions have shown pricing improvements in some segments, which we hope will persist.
Q: Regarding the $300 million contract signed in October 2024, with the rupee depreciating from 84 to 96 per dollar, does the company stand to benefit from higher rupee revenues? A: (Unidentified_4) We are naturally hedged at a company level due to significant dollar-based imports. While there may be some positive impact, it won't be as straightforward as the currency change suggests, given our sourcing and import dynamics.
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
